-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Isochlorogenic acid C
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/57378-72-0.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 57378-72-0 |
| Description | Isochlorogenic acid C is extracted from the flower bud of Lonicera japonica Thunb. Isochlorogenic acid C is a selective inhibitor of human immunodeficiency virus type 1 integrase. It has antioxidant activity. |
Product Information
| Synonyms | Cyclohexanecarboxylic acid, 3,4-bis[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl]oxy]-1,5-dihydroxy-, (1R,3R,4S,5R)-; (1R,3R,4S,5R)-3,4-Bis[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl]oxy]-1,5-dihydroxycyclohexanecarboxylic acid; Cyclohexanecarboxylic acid, 3,4-bis[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,5-dihydroxy-, (1R,3R,4S,5R)-; Cyclohexanecarboxylic acid, 3,4-bis[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,5-dihydroxy-, [1R-(1α,3α,4α,5β)]-; 4,5-Dicaffeoylquinic acid; Isochlorogenic acid c |
| IUPAC Name | (1R,3R,4S,5R)-3,4-bis[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,5-dihydroxycyclohexane-1-carboxylic acid |
| Molecular Weight | 516.45 |
| Molecular Formula | C25H24O12 |
| Canonical SMILES | C1C(C(C(CC1(C(=O)O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)OC(=O)C=CC3=CC(=C(C=C3)O)O)O |
| InChI | InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(31)36-20-12-25(35,24(33)34)11-19(30)23(20)37-22(32)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-30,35H,11-12H2,(H,33,34)/t19-,20-,23+,25-/m1/s1 |
| InChIKey | UFCLZKMFXSILNL-GCBRTHAASA-N |
| Boiling Point | 810.8±65.0°C at 760 mmHg |
| Melting Point | 140 °C |
| Purity | ≥95% |
| Density | 1.64±0.1 g/cm3 |
| Solubility | Soluble in DMF, DMSO |
| Appearance | White Powder |
| Application | Antiviral activity, including anti-HIV-1 integrase activity. |
| Shelf Life | As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly |
| Storage | Store at -20°C |
| Exact Mass | 530.14200 |
| In Vitro | 4,5-Dicaffeoylquinic acid (0.1~100 µM; 72 h) has dose-dependent inhibitory activity against DU-145 prostate cancer cells, and induces cell cycle arrest, also induces inactivation of Bcl-2. 4,5-Dicaffeoylquinic acid (1~100 µg/mL; 48 h) has anti-apoptotic effect in D-GalN-challenged HL-7702 hepatocytes, and improves significantly cell viability at concentrations of 10 to 100 µg/mL. 4,5-Dicaffeoylquinic acid (1~100 µg/mL; 4 days) inhibits significantly expressions of HBsAg and HBeAg, and produces the maximum inhibition rates of 86.93 and 59.79% at 100 µg/mL on expressions of HBsAg and HBeAg, respectively. |
| In Vivo | 4,5-Dicaffeoylquinic acid enhances the expression of GLUT2, GK, and PDX-1 protein, and effectively alleviate glycaemia and insulin resistance and enhance insulin sensitivity in type 2 diabetic mice. |
| PSA | 200.28000 |
| Target | HBV; Endogenous Metabolite; Apoptosis; Glucosidase |
